Literature DB >> 30836124

The anti-hyperglycemia effects of Rhizoma Coptidis alkaloids: A systematic review of modern pharmacological studies of the traditional herbal medicine.

Hang Ma1, Kai He2, Jianwei Zhu3, Xuegang Li4, Xiaoli Ye5.   

Abstract

Hyperglycemia is a common endocrine system disease, which seriously affects people's health with a increasing morbidity in recent years. Rhizoma Coptidis (RC), one of the most commonly used traditional Chinese medicines, has been applied to treat diabetes in clinic for thousands of years. Since scientists demonstrated that alkaloids from RC owned the amazing anti-hyperglycemia activities 30 years ago, these compounds have been widely used for the treatment of diabetes and hyperglycemia with unconspicuous toxicities and side effects. With the help of molecular biology, immunology and other techniques, the mechanisms about anti-hyperglycemia effect of RC alkaloids have been extensively discussed. Numerous studies showed that RC alkaloids balanced the glucose homeostasis not only by widely recognizing insulin resistance pathways, but also by promoting insulin secretion, regulating intestinal hormones, ameliorating gut microbiota structures and many other ways. In this review, we combine the latest advances and systematically summarize the mechanisms of RC alkaloids in treating hyperglycemia and diabetic nephropathy to provide a deeper understanding of these natural alkaloids. In addition, the important role of gut microbiota associated with the glucose metabolism is also reviewed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alkaloids; Berberine; Diabetic nephropathy; Hyperglycemia; Rhizoma Coptidis

Mesh:

Substances:

Year:  2019        PMID: 30836124     DOI: 10.1016/j.fitote.2019.03.003

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  6 in total

1.  Preparation of magnetic yolk-shell structured metal-organic framework material and its application in pharmacokinetics study of alkaloids.

Authors:  Shi-Jun Yin; Xu Wang; Hui Jiang; Min Lu; Xi Zhou; Li-Xian Li; Feng-Qing Yang
Journal:  Anal Bioanal Chem       Date:  2021-09-17       Impact factor: 4.142

2.  UPLC-Q-TOF/MS-Based Serum and Urine Metabonomics Study on the Ameliorative Effects of Palmatine on Helicobacter pylori-Induced Chronic Atrophic Gastritis.

Authors:  Xing Chen; Jianzhong Zhang; Ruilin Wang; Honghong Liu; Chunmei Bao; Shihua Wu; Jianxia Wen; Tao Yang; Ying Wei; Sichen Ren; Yuling Tong; Yanling Zhao
Journal:  Front Pharmacol       Date:  2020-09-15       Impact factor: 5.810

3.  The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial.

Authors:  Yueh-Hsiang Huang; Szu-Tah Chen; Feng-Hsuan Liu; Sheng-Hwu Hsieh; Chia-Hung Lin; Miaw-Jene Liou; Chih-Ching Wang; Chung-Huei Huang; Geng-Hao Liu; Jr-Rung Lin; Lan-Yan Yang; Tzu-Yang Hsu; Ming-Chung Lee; Chun-Teng Huang; Yi-Hong Wu
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

4.  Mechanisms of Rhizoma Coptidis against type 2 diabetes mellitus explored by network pharmacology combined with molecular docking and experimental validation.

Authors:  Wenrong An; Yanqin Huang; Shouqiang Chen; Tao Teng; Yingning Shi; Zhenhai Sun; Yunsheng Xu
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

5.  Exploring the Regulatory Mechanism of Modified Huanglian Maidong Decoction on Type 2 Diabetes Mellitus Biological Network Based on Systematic Pharmacology.

Authors:  Qi He; Tianqing Zhang; Bing Jin; Yonghe Wu; Jiamin Wu; Pu Gao; Shiwei Wu
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-12       Impact factor: 2.629

6.  The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Jing Guo; Hongdong Chen; Xueqin Zhang; Wenjiao Lou; Pingna Zhang; Yuheng Qiu; Chao Zhang; Yaoxian Wang; Wei Jing Liu
Journal:  Oxid Med Cell Longev       Date:  2021-12-15       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.